Cosmos Health (NASDAQ:COSM) announced the U.S. launch of Fort18™, a men’s sexual stamina supplement joining its 18 Series on May 6, 2026. Fort18™ uses a proprietary five-ingredient botanical blend standardized to ≥20% saponins and 1.5% flavonoids and is dosed at 500mg twice daily.
Published clinical research (randomized, double-blind, placebo-controlled; n=60) reported a 5.1-fold improvement in endurance versus placebo over eight weeks, with onset by Week 4. IP for the blend’s standardization fingerprint is held by the ingredient supplier.
Loading…
Loading translation…
Positive
Published clinical result: 5.1-fold endurance improvement vs placebo
Market opportunity: U.S. sexual health supplement market projected to $1.93B by 2030
Clinical-consistent dosing: Fort18 formulated at 500mg twice daily as in study
Patent-protected standardization for the active blend
Negative
Small clinical sample: published study enrolled 60 men
IP held by supplier: standardization fingerprint owned by ingredient supplier, not Cosmos Health
Endurance improvement
5.1-fold vs placebo
Published human study over 8 weeks for Fort18 active ingredient
Study population
60 men
Healthy men aged 18–60 with reduced sexual stamina
Study duration
8 weeks
Randomized, double-blind, placebo-controlled trial
Fort18 dose
500 mg twice daily
Formulation dose matched to published clinical research
Saponins content
≥20% saponins
Standardization of the five-ingredient botanical blend
Flavonoids content
≥1.5% total flavonoids
Standardization of the Fort18 proprietary blend
Global market 2023
$3.52 billion
Global sexual health supplement market size in 2023
US market 2030
$1.93 billion
Projected U.S. sexual health supplement market by 2030
$0.3550
Last Close
Volume
Volume 380,983 is below the 20-day average of 1,617,603, suggesting muted pre-news activity.
low
Technical
Shares at $0.355, trading below the $0.62 200-day moving average, indicating a prior downtrend.
COSM slipped 0.56% while peers were mixed: SNYR up 1.34%, ZYXI down 37.34%, others modestly negative or flat. This points to stock-specific dynamics rather than a coordinated sector move.
Date
Event
Sentiment
Move
Catalyst
Apr 30
Revenue projection
Positive
+2.5%
Cur18 projected to add over $2.5M in annual U.S. revenue.
Apr 17
Product launch
Positive
+0.1%
Planned Q2 U.S. launch of Cur18 with enhanced bioavailability data.
Apr 13
Commercial order
Positive
+8.5%
Third Pharmalink order lifts cumulative Sky Premium Life units to 270,000.
Apr 10
Operational update
Positive
+3.5%
Record revenue momentum and NOOR U.S. expansion projections disclosed.
Apr 08
Product launch
Positive
+0.6%
Announcement of Q2 U.S. launch of Liv18 for liver fat reduction.
Pattern Detected
Recent crypto-tag headlines have generally been followed by modest positive price moves, suggesting the stock has reacted constructively to prior growth and expansion news.
Recent Company History
Over the past month, Cosmos Health has reported multiple expansion-focused updates under the crypto tag, including UAE purchase orders, Liv18 and Cur18 U.S. launches, and strong Q3 2025 financial momentum. Price reactions to these items were mostly positive, with moves between 0.07% and 8.5%. Today’s Fort18 launch continues the build-out of the 18 Series in the U.S., extending a pattern of product-driven growth announcements supported by clinical and commercial detail.
+3.0%
Average Historical Move
crypto
In recent months, COSM’s crypto-tag news around U.S. product launches and orders averaged a 3.02% move, so the Fort18 launch fits an ongoing expansion narrative.
Same-tag history shows steady expansion of Cosmos’s U.S. footprint, from Liv18 and Cur18 launches to repeat UAE orders and revenue milestones, now extended by Fort18 in men’s wellness.
An active S-3/A filed on 2026-04-24 registers 73,523,716 common shares for resale by selling stockholders, linked to note conversions at a $0.176 floor price. As of April 23, 2026, 52,617,105 shares were outstanding with a pro forma 126,054,324 post-offering figure. The filing is not yet effective and shows no usage to date.
This announcement adds Fort18, a clinically researched men’s sexual stamina supplement, to Cosmos Health’s 18 Series, targeting a U.S. market projected at $1.93B by 2030. The active ingredient showed a 5.1-fold endurance improvement over placebo in a 60-patient, 8-week trial. Historically, similar crypto-tag updates around product launches and orders produced average moves of 3.02%. Investors may watch execution on U.S. distribution, competitive dynamics, and the impact of the registered 73,523,716 resale shares under the S-3/A.
randomized, double-blind, placebo-controlled
medical
“Study design | Randomized, double-blind, placebo-controlled”
A “randomized, double-blind, placebo-controlled” process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.
placebo
medical
“reported a 5.1-fold improvement in endurance over the placebo group”
A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.
nitric oxide
medical
“supports healthy blood flow through nitric oxide-related pathways”
A simple signaling molecule made of one nitrogen and one oxygen atom that acts like a tiny messenger in the body, telling blood vessels to widen, controlling breathing and influencing immune responses. Investors care because products that deliver, mimic, or measure this gas—such as inhaled therapies, drugs that boost its effects, or diagnostic tests—can affect patient outcomes, regulatory approvals and market value; think of it as a traffic controller for blood and air flow whose tools can become investable medical products.
dopamine
medical
“Mucuna seed extract: studied for its support of dopamine-related pathways”
A chemical messenger in the brain that helps control movement, motivation, pleasure and learning; think of it as a courier delivering signals that tell cells when to act. Investors care because drugs, devices or therapies that change dopamine levels can treat major illnesses (like Parkinson’s, depression or addiction), driving clinical trials, regulatory decisions and market demand, so developments can materially affect company value and risk.
cagr
financial
“growing at a CAGR of 10.4%”
Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.
AI-generated analysis. Not financial advice.
05/06/2026 – 10:35 AM
Science-based men’s wellness: Fort18™ is formulated with a proprietary five-ingredient botanical blend intended to support men’s sexual stamina
Large and growing market: The U.S. sexual health supplement market is projected to reach $1.93 billion by 2030
Expanding the 18 Series: Fort18™ joins Noor18™, Liv18™, and Cur18™ – advancing the target of 18 science-based products spanning key health categories
CHICAGO, IL / ACCESS Newswire / May 6, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the introduction of Fort18™ in the United States – a men’s sexual stamina supplement formulated with a proprietary blend of botanical extracts and nutrients that has been evaluated in published clinical research.
Fort18™ is the latest addition to the Company’s “18 Series,” entering a large and growing market with a science-based formulation supported by published human clinical data. It is estimated that a significant proportion of men globally may experience reduced sexual stamina and endurance, and are increasingly seeking solutions supported by clinical research.
Published Clinical Research
Published clinical research on the active ingredient (Journal of Medicinal Food, September 2020) has reported a 5.1-fold improvement in endurance over the placebo group over eight weeks, with results observed as early as Week 4 of the study. The following summarizes key findings from published clinical research on the active ingredient:
Parameter
Detail
Study design
Randomized, double-blind, placebo-controlled
Population
60 healthy men, aged 18-60, experiencing reduced sexual stamina
Duration
8 weeks
Key finding
Published research has reported a 5.1-fold improvement in endurance over the placebo group
Onset
Results observed as early as Week 4 of the published study
Safety observations
No significant changes noted in vital signs or blood, serum, or urine markers during the study period
IP status
Exclusive and patent-protected standardization fingerprint, held by ingredient supplier
Formulation
Fort18™ is formulated with a proprietary blend of five botanical extracts and nutrients – L-arginine and extracts of mucuna, fenugreek, ashwagandha, and artichoke – collectively standardized to a minimum of 20% saponins and 1.5% total flavonoids. The blend is designed to collectively support the hormonal, neuronal, and vascular pathways associated with male sexual stamina and endurance, drawing on botanical ingredients with a long history of use in traditions such as Ayurveda and Traditional Chinese Medicine:
Artichoke leaf extract: supports healthy blood flow through nitric oxide-related pathways
Fenugreek seed extract: associated with support of arousal, energy, and stamina in published research
Ashwagandha root extract: an adaptogenic botanical supporting a healthy stress response and nervous system function
Mucuna seed extract: studied for its support of dopamine-related pathways and male wellness
L-Arginine: an amino acid associated with vascular support and healthy blood flow through nitric oxide production
The formulation’s standardization fingerprint is exclusive and patent-protected. Fort18™ is formulated at 500mg twice per day – consistent with the dose evaluated in published clinical research.
Market Context
According to Grand View Research, the global sexual health supplement market was estimated at $3.52 billion in 2023 and is projected to reach $7.02 billion by 2030, growing at a CAGR of 10.4%. The United States is one of the largest individual markets globally, accounting for an estimated 27.4% of the global market – estimated at $965.8 million in 2023 and projected to reach $1.93 billion by 2030, representing a near-doubling of market size over the period, per Grand View Horizon. Male consumers represent more than 55% of the global consumer base for sexual health supplements, per Market.us.
Greg Siokas, CEO of Cosmos Health, stated: “The men’s wellness category represents a significant and growing market opportunity, and one where consumers are increasingly seeking products with credible scientific substantiation. The introduction of Fort18™ – formulated with a proprietary botanical blend backed by published clinical research – is an important step in the expansion of our 18 Series into the United States, and we believe it has the potential to become a meaningful contributor to our broader nutraceutical portfolio.”
About the 18 Series
Fort18™ is the latest addition to the Company’s “18 Series” – a portfolio of science-based nutraceutical products where every product is designed to meet three defined criteria: a proprietary ingredient backed by published research, published clinical studies supporting its intended use, and dosing consistent with published clinical research. The Company notes that these criteria reflect a rigorous approach to ingredient selection consistently applied across the portfolio.
The Company has a strategic target of 18 products spanning key health categories. In addition to Fort18™, other current 18 Series products include Noor18™ (marine collagen, anti-aging; proprietary formulation held by ingredient supplier), Liv18™ (liver fat support; active ingredient covered by a granted patent held by ingredient supplier), and Cur18™ (next-generation curcumin; active ingredient utilizing patent-protected proprietary technology held by ingredient supplier).
Cosmos Health sources its active ingredients from established suppliers and all products are manufactured in the United States under applicable quality and regulatory standards.
These products are dietary supplements. Statements regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
What is Fort18™ from Cosmos Health (COSM) and when was it launched in the U.S.?
Fort18™ is a men’s sexual stamina supplement launched May 6, 2026. According to Cosmos Health, it joins the 18 Series and is formulated with a five-ingredient botanical blend standardized for saponins and flavonoids.
What clinical evidence supports Fort18™ (COSM) claims about endurance?
A published randomized, double-blind, placebo-controlled study reported a 5.1-fold endurance improvement over eight weeks. According to Cosmos Health, results appeared as early as Week 4 in the 60-participant study.
How is Fort18™ dosed compared with the clinical study for Cosmos Health (COSM)?
Fort18™ is formulated at 500mg taken twice daily, matching the dose evaluated in the published clinical research. According to Cosmos Health, the product replicates the study dosing regimen.
Who holds the intellectual property for Fort18™’s standardized blend used by Cosmos Health (COSM)?
The standardization fingerprint is exclusive and patent-protected but held by the ingredient supplier. According to Cosmos Health, the supplier controls the IP rather than Cosmos Health itself.
How large is the U.S. market opportunity for Fort18™ (COSM) in sexual health supplements?
The U.S. sexual health supplement market is projected to reach $1.93 billion by 2030. According to Cosmos Health, the U.S. represented about 27.4% of the global market in 2023.